Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-05-03
2005-05-03
Andres, Janet (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007950, C514S002600, C530S350000, C424S198100
Reexamination Certificate
active
06887674
ABSTRACT:
Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.
REFERENCES:
patent: 5624899 (1997-04-01), Bennett et al.
patent: 5635177 (1997-06-01), Bennett et al.
patent: 5864020 (1999-01-01), Bennett et al.
patent: 6303769 (2001-10-01), Cerretti et al.
patent: 6413730 (2002-07-01), Holland et al.
patent: 6479459 (2002-11-01), Cerretti et al.
patent: 6492140 (2002-12-01), Cerretti et al.
patent: 6514497 (2003-02-01), Briskin et al.
patent: 20020146420 (2002-10-01), Bennett et al.
patent: 0 633 315 (1993-03-01), None
patent: 0999 278 (2000-05-01), None
patent: WO 9315201 (1993-08-01), None
patent: WO 9626958 (1996-09-01), None
patent: WO 9952541 (1998-04-01), None
patent: WO 9845708 (1998-10-01), None
patent: WO 9908696 (1999-02-01), None
patent: WO 0024413 (2000-05-01), None
patent: WO 0030673 (2000-06-01), None
patent: WO 0030673 (2000-06-01), None
patent: WO 0211785 (2002-02-01), None
patent: WO 0226827 (2002-04-01), None
patent: WO 02058538 (2002-08-01), None
patent: WO 02061055 (2002-08-01), None
patent: WO 02079382 (2002-10-01), None
patent: WO 02102973 (2002-12-01), None
patent: WO 03004057 (2003-01-01), None
The Eph Nomenclature Committee, Cell, 1997, vol. 90, pp. 403-404.*
Pandey et al., Science, 1996, vol. 268, pp. 567-569.*
Pasquale, Current Opinion in Cell Biology, 1997, vol. 9, pp. 608-615.*
Yancopoulos, G. D., et al., “Vasculogenesis, Angiogenesis and Growth Factors: Ephrins Enter the Fray at the Border,”Cell, 93:661-664 (1998).
Stein, E., et al., “Eph Receptors Discriminate Specific Ligand Oligomers to Determine Alternative Signaling Complexes, Attachment, and Assembly Responses,”Genes Dev., 12:667-678 (1998).
Stein, E. et al., “Nck Recruitment to Eph Receptor, EphB1/ELK, Couples Ligand Activation to c-Jun Kinase,”J. Biol. Chem., 273(3):1303-1308 (1998).
Adams, R.H., et al., “Roles of ephrinB Ligands and EphB Receptors in Cardiovascular Development: Demarcation of Arterial/Venous Domains, Vascular Morphogenesis, and Sprouting Angiogenesis,”Genes Dev. 13:295-306 (1999).
Gerety, S.S., et al., “Symmetrical Mutant Phenotypes of the ReceptorEphB4and Its Specific Transmembrane Ligandephrin-B2in Cardiovascular Development,”Mol. Cell, 4:403-414 (1999).
Gale, N.W., et al., “Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells,”Dev. Biol., 230: 151-160 (2001).
Bennett, B. D. et al., “Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1866-1870, Mar. 1995.
Bergemann, A. D. et al., “ELF-2, a New Member of the Eph Ligand Family, Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites,”Molecular and Cellular Biology, vol. 15, No. 9, pp. 4921-1929, Sep. 1995.
Wang, H., “Transmembrane Ephrin Ligands in Neural and Vascular Development,”DAI, 59(11) : 5721 (1999).
Andres, A.C. et al., “Expression of two noveleph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis,”Oncogene, vol. 9, pp. 1461-1467, 1994.
Folkman, J. et al., “Blood Vessel Formation: What Is Its Molecular Basis?,”Cell, vol. 87, pp. 1153-1155, Dec. 27, 1996.
Risau, W., Mechanisms of angiogenesis,Nature, vol. 386, pp. 671-674, Apr. 17, 1997.
Pasquale, E. B., “The Eph family of receptors,”Curr. Opin. Cell. Biol. 9:608-615, 1997.
Wang, H. U. et al., “Eph Family Transmembrane Ligands Can Mediate Repulsive Guidance of Trunk Neural Crest Migration and Motor Axon Outgrowth,”Neuron, vol. 18, pp. 383-396, Mar. 1997.
Asahara, T. et al., “Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,”Science, vol. 275, pp. 964-967, Feb. 14, 1997.
Wang, H. U. et al., “Molecular Distinction and Angiogenic Interaction between Embryonic Arteries and Veins Revealed by ephrin-B2 and Its Receptor Eph-B4,”Cell, vol. 93, pp. 741-753, May 29, 1998.
Simonet, S., et al., “Venous and Arterial Endothelial Cells Respond Differently to Thrombin and its Endogenous Receptor Agonist,”European Journal of Pharmacology216: 135-137 (1992).
Anderson David J.
Chen Zhoufeng
Wang Hai U.
California Institute of Technology
Ropes & Gray LLP
LandOfFree
Artery- and vein-specific proteins and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Artery- and vein-specific proteins and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Artery- and vein-specific proteins and uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368609